美国食品和药物管理局采取措施收回生猪药物卡巴多的批准

　　US - The US Food and Drug Administration’s Center for Veterinary Medicine (CVM) has taken the first step toward withdrawing its approval of the use of carbadox to treat swine as the drug may leave trace amounts of a carcinogenic residue.CVM’s action comes after the center recently reexamined the safety profile of the drug and conducted a preliminary risk characterization that indicated there could be potential risk to human health from ingesting pork, especially pork liver, derived from carbadox-treated pigs.“The manufacturer of carbadox has failed to provide sufficient scientific data to demonstrate the safety of this drug given evidence that carbadox may result in carcinogenic residues,” said Michael R. Taylor, FDA deputy commissioner for foods and veterinary medicine.

　　由于卡巴多(carbadox)约摸留下微量的致癌残渣，美国食品和药物管理局(FDA)的兽医中央(CVM)已经迈出首席步，收归药物卡巴多在生猪饲养中的使用审批。兽医中央最近在举动之前重新审查了药物的安全性并进行初步风险评估。评估能显示出摄取猪肉对人体健康的潜在风险，尤其是使用卡巴多的生猪猪肝。美国食品和药物管理局副局长迈克尔·泰勒(Michael R. Taylor)说：“有证据显示卡巴多约摸引起致癌残渣，而卡巴多创造商不能提供充沛的科学依据证明药品的安全性。”